The Influence of Target Protein Half-Life on the Effectiveness of Antisense Oligonucleotide Analog-Mediated Biologic Responses
- 1 August 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 8 (4) , 281-293
- https://doi.org/10.1089/oli.1.1998.8.281
Abstract
During the course of a study aimed at improving antisense oligodeoxynucleotide-mediated ex vivo bone marrow purging of patients suffering from chronic myeloid leukemia (CML), the properties of a number of antisense structures intended to reduce the expression of c-myc, mutant p53, and bcr-abl mRNAs and proteins were examined. The majority of the antisense oligodeoxynucleotides were designed to be capable of directing ribonuclease H (RNase H) cleavage of their target mRNAs. Streptolysin O (SLO) reversible permeabilization was used to deliver the oligodeoxynucleotides into the CML line KYO-1. We found that the efficiency and specificity of antisense oligonucleotide-induced reductions of target protein expression depended on target protein half-life, the oligonucleotide structure, and the specific sequence within the target mRNA. Transient reductions of c-myc mRNA and protein were achieved with a chimeric methylphosphonate-phosphodiester oligodeoxynucleotide antisense to the initiation codon, but cell proliferation was unaffected. In contrast, a chimeric oligodeoxynucleotide of similar structure targeted to an alternative site in the coding region of c-myc mRNA reduced target mRNA and protein levels for over 24 hours and halted cell proliferation. Chimeric methylphosphonate-phosphodiester oligodeoxynucleotide antisense to a point mutation in KYO-1 p53 mRNA efficiently reduced target mRNA expression, but only small, transient reductions in p53 protein expression were observed. However, a chimeric methylphosphonate-phosphorothioate oligodeoxynucleotide targeted to the same site reduced p53 protein to 30% of control levels over a 48-hour period. BCR-ABL protein expression was unaffected by chimeric oligodeoxynucleotides targeted to the breakpoint in bcr-abl mRNA, even when mRNA levels at early times were substantially reduced.Keywords
This publication has 27 references indexed in Scilit:
- Enhanced Antisense Effects Resulting from an Improved Streptolysin-O Protocol for Oligodeoxynucleotide Delivery into Human Leukaemia CellsNucleosides and Nucleotides, 1997
- Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potencyNucleic Acids Research, 1996
- Does antisense exist?Nature Medicine, 1995
- Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cellsNucleic Acids Research, 1995
- Gene inhibition using antisense oligodeoxynucleotidesNature, 1994
- Electroporation enhances c-myc antisense oligodeoxynucleotide efficacyNucleic Acids Research, 1993
- Cell cycle regulation of the glyceraldehyde3phosphate dehydrogenaseluracil DNA glycosylase gene in normal human cellsNucleic Acids Research, 1993
- Non-radioactive labeling of RNA transcriptsin vitrowith the hapten digoxigenin (DIG); hybridization and ELISA-based detectionNucleic Acids Research, 1990
- Physicochemical properties of phospborothioate oligodeoxynucleotidesNucleic Acids Research, 1988
- Isolation and characterization of the human cellular myc gene productBiochemistry, 1985